Acute Liver Failure – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Acute Liver Failure – Drugs In Development, 2024 report and make more profitable business decisions.
Acute liver failure is a rare but life-threatening condition that occurs when the liver loses most of its function in a short period of time. It can be caused by various factors, such as viral infections, drug overdose, autoimmune diseases, or metabolic disorders. Some of the common signs and symptoms of acute liver failure are jaundice, bleeding, confusion, and coma. Acute liver failure requires urgent medical attention and may need a liver transplant in some cases. Treatment options depend on the cause and severity of the condition.
The Acute Liver Failure drugs in development market research report provide comprehensive information on the therapeutics under development for Acute Liver Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Liver Failure and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Acute Liver Failure | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 31 molecules, with 27 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Acute Liver Failure therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Acute Liver Failure pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Acute Liver Failure treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Akaza Bioscience LtdArch Biopartners Inc
Cellaion SA
Evive Biotech
Genesen Co Ltd
Genfit SA
Glycan Therapeutics Inc
GNI Group Ltd
GoLiver Therapeutics
Guangzhou Saijun Biological Technology Co Ltd
HepaRegeniX GmbH
Huaxia Source Cell Engineering Group Co Ltd
King's College Hospital NHS Trust R&D Consortium
Mitopower LLC
PrimeGen Global Inc
Proterris Inc
SeaBeLife Spas
Shanghai Hexaell Biotech Co Ltd
Shenzhen Wingor Biotechnology Co Ltd
Shiftbio Co Ltd
Sun Yat-sen University
The Healthy Aging Co
The Queen’s Medical Research Institute
Tianjin Angsai Cell Genetic Engineering Co Ltd
Unicyte AG
University of Edinburgh
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Acute Liver Failure reports